ELIGIBILITY FORM

	INCLUSION CRITERIA	Yes	No
1	Histologically confirmed soft-tissue sarcoma by central review, except if the diagnosis was already confirmed by the RRePS Network	❑	❑
2	Available archived frozen tumor tissue sample. In case of insufficient archived tumor sample in quantity and/or in quality for the realization of planned molecular analysis,a new microbiopsy of the tumour will be performed in consenting patients. This microbiopsy must be in expert center labelled by the French National Cancer Institute (NETSARC)	❑	❑
3	Non-metastatic disease, for which the use of chemotherapy to "downstage" the sarcoma prior to surgery, is assumed to result in better local tumor control by the multidisciplinary sarcoma team of one of the French reference centers involved in this study	❑	❑
4	Age ≥18 years.	❑	❑
5	Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1	❑	❑
6	Measurable disease according to RECIST v1.1 outside any previously irradiated field.	❑	❑
7	Neoadjuvant anthracycline-based chemotherapy proposed as the best option by the multidisciplinary sarcoma team of one of the French reference centers involved in this study.	❑	❑
8	No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma.	❑	❑
9	Voluntarily signed and dated written informed consents prior to any study specific procedure.	❑	❑
10	Patients with a social security in compliance with the French Law relating to biomedical research (Article 1121-11 of French Public Health Code).	❑	❑

A single « NO » excludes the patient

	NON-INCLUSION CRITERIA	Yes	No
1	Pathological diagnosis different from a soft-tissue sarcoma.	❑	❑
2	Histological subtypes: well-differentiated liposarcoma, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, alveolar or embryonal rhabdomyosarcoma.	❑	❑
3	Previous treatment for the sarcoma.	❑	❑
4	Contra-indication precluding the administration of chemotherapy as assessed by the investigator.	❑	❑
5	Participation to a study involving a medical or therapeutic intervention in the last 30 days.	❑	❑
6	Previous enrolment in the present study.	❑	❑
7	Pregnant and breast feeding women.	❑	❑
8	Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.	❑	❑
9	Contra-indication precluding the administration of contrast agent for patients requiring a tumor evaluation with contrast injection (CT-scan or RMI)	❑	❑

A single « YES » excludes the patient

Date : |__|__|/ |__|__|/ |__|__|__|__| Signature Investigateur :